ES2890126T3 - Métodos y composiciones para la obtención clínica de una célula alogénica y usos terapéuticos - Google Patents

Métodos y composiciones para la obtención clínica de una célula alogénica y usos terapéuticos Download PDF

Info

Publication number
ES2890126T3
ES2890126T3 ES17191442T ES17191442T ES2890126T3 ES 2890126 T3 ES2890126 T3 ES 2890126T3 ES 17191442 T ES17191442 T ES 17191442T ES 17191442 T ES17191442 T ES 17191442T ES 2890126 T3 ES2890126 T3 ES 2890126T3
Authority
ES
Spain
Prior art keywords
cells
culture
cell
stem cells
umbilical cord
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES17191442T
Other languages
English (en)
Spanish (es)
Inventor
Amit Patel
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48698707&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2890126(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Individual filed Critical Individual
Application granted granted Critical
Publication of ES2890126T3 publication Critical patent/ES2890126T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0681—Cells of the genital tract; Non-germinal cells from gonads
    • C12N5/0682—Cells of the female genital tract, e.g. endometrium; Non-germinal cells from ovaries, e.g. ovarian follicle cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • C12N5/0665—Blood-borne mesenchymal stem cells, e.g. from umbilical cord blood
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/48—Reproductive organs
    • A61K35/51—Umbilical cord; Umbilical cord blood; Umbilical stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0603—Embryonic cells ; Embryoid bodies
    • C12N5/0605—Cells from extra-embryonic tissues, e.g. placenta, amnion, yolk sac, Wharton's jelly
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0653—Adipocytes; Adipose tissue
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0654—Osteocytes, Osteoblasts, Odontocytes; Bones, Teeth
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0655—Chondrocytes; Cartilage
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0657—Cardiomyocytes; Heart cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Reproductive Health (AREA)
  • Hematology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Cardiology (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
ES17191442T 2011-12-30 2012-12-31 Métodos y composiciones para la obtención clínica de una célula alogénica y usos terapéuticos Active ES2890126T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161582070P 2011-12-30 2011-12-30
US201261591211P 2012-01-26 2012-01-26

Publications (1)

Publication Number Publication Date
ES2890126T3 true ES2890126T3 (es) 2022-01-17

Family

ID=48698707

Family Applications (2)

Application Number Title Priority Date Filing Date
ES17191442T Active ES2890126T3 (es) 2011-12-30 2012-12-31 Métodos y composiciones para la obtención clínica de una célula alogénica y usos terapéuticos
ES12862921.9T Active ES2656614T3 (es) 2011-12-30 2012-12-31 Métodos y composiciones para la derivación clínica de células alogénicas y sus usos terapéuticos

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES12862921.9T Active ES2656614T3 (es) 2011-12-30 2012-12-31 Métodos y composiciones para la derivación clínica de células alogénicas y sus usos terapéuticos

Country Status (12)

Country Link
US (8) US9803176B2 (enExample)
EP (2) EP2798058B1 (enExample)
JP (1) JP6548897B2 (enExample)
CA (2) CA3113484A1 (enExample)
DK (1) DK3321355T3 (enExample)
ES (2) ES2890126T3 (enExample)
HR (1) HRP20211373T1 (enExample)
HU (1) HUE056817T2 (enExample)
PL (1) PL3321355T3 (enExample)
PT (1) PT3321355T (enExample)
SI (1) SI3321355T1 (enExample)
WO (1) WO2013102219A1 (enExample)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5505760B2 (ja) 2005-09-27 2014-05-28 ティッシュテク・インコーポレーテッド 羊膜調製物及び精製組成物及びその使用方法
US9526770B2 (en) 2011-04-28 2016-12-27 Tissuetech, Inc. Methods of modulating bone remodeling
US9682044B2 (en) 2011-06-10 2017-06-20 Tissuetech, Inc. Methods of processing fetal support tissues, fetal support tissue powder products, and uses thereof
US10167448B2 (en) 2013-12-12 2019-01-01 Samsung Life Public Welfare Foundation Pharmaceutical composition for treating cerebrovascular diseases, containing stem cell-derived exosome as active ingredient
WO2015142061A1 (ko) 2014-03-18 2015-09-24 사회복지법인 삼성생명공익재단 줄기세포 유래 엑소좀을 유효성분으로 포함하는 뇌 염증성 질환의 치료용 조성물
WO2015179711A1 (en) * 2014-05-21 2015-11-26 Mimedx Group, Inc. Micronized wharton's jelly
TW201603818A (zh) 2014-06-03 2016-02-01 組織科技股份有限公司 組成物及方法
EP3167049A4 (en) 2014-07-08 2017-11-29 MIMEDX Group Inc. Micronized wharton's jelly
US20160243288A1 (en) 2015-02-23 2016-08-25 Tissuetech, Inc. Apparatuses and methods for treating ophthalmic diseases and disorders
US10342831B2 (en) 2015-05-20 2019-07-09 Tissuetech, Inc. Composition and methods for preventing the proliferation and epithelial-mesenchymal transition of epithelial cells
JP6648259B2 (ja) * 2015-08-12 2020-02-14 チャ バイオテック カンパニー リミテッド 向上された臍帯由来付着型幹細胞、その製造方法及びその用途
US12551509B2 (en) 2015-11-18 2026-02-17 Lucina Patent Holdco, Llc Acellular regenerative products and methods of their manufacture
TW201733600A (zh) 2016-01-29 2017-10-01 帝聖工業公司 胎兒扶持組織物及使用方法
EP3474869B1 (en) * 2016-06-24 2025-04-09 Osiris Therapeutics, Inc. Human tissue derived compositions and uses thereof
KR102048228B1 (ko) 2016-12-02 2019-11-25 가톨릭대학교 산학협력단 Ｔ 세포 자극용 엑소좀 및 이의 약제학적 용도
KR101864234B1 (ko) * 2017-07-04 2018-06-04 인하대학교 산학협력단 음경해면체 유래 엑소좀을 유효성분으로 포함하는, 발기부전 예방, 개선 또는 치료용 조성물
US11285177B2 (en) 2018-01-03 2022-03-29 Globus Medical, Inc. Allografts containing viable cells and methods thereof
CN108239621B (zh) * 2018-01-24 2020-08-18 北京臻溪谷医学研究中心（有限合伙） 一种胎盘亚全能干细胞分离、扩增、冻存、复苏干细胞的方法
EP3911344A4 (en) 2019-01-16 2022-10-19 University of Utah Research Foundation MESENCHYMAL STEM CELL LAYERS FROM HUMAN UMBILICAL CORD AND PROCESS FOR THEIR PRODUCTION
JP7585207B2 (ja) * 2019-01-16 2024-11-18 ユニバーシティ オブ ユタ リサーチ ファウンデーション 子宮瘢痕形成を予防するための間葉系幹細胞シートの使用
JP7717712B2 (ja) * 2020-03-09 2025-08-04 エスエムエスバイオテック インコーポレイテッド 幹細胞組成物および組織を修復する方法
US20230338428A1 (en) * 2020-09-08 2023-10-26 Amit Patel Allogenic umbilical cord stem cells for treating severe respiratory conditions
US20230057957A1 (en) * 2021-08-23 2023-02-23 Therapeutic Solutions International, Inc. Umbilical cord mesenchymal stem cells for treatment of chronic obstructive pulmonary disease and lung degeneration
EP4460697A4 (en) * 2022-01-07 2026-06-24 Mercy Bioanalytics Inc COMPOSITIONS AND METHODS FOR THE DETECTION OF LUNG CANCER
US20230295569A1 (en) * 2022-03-15 2023-09-21 Creative Medical Technologies, Inc. Therapeutic regenerative cells
US20230293598A1 (en) * 2022-03-15 2023-09-21 Narkeshyo LLC Prevention of radiation exposure associated pathology by treatment with umbilical cord derived regenerative cells
US20230364148A1 (en) * 2022-05-12 2023-11-16 Therapeutic Solutions International, Inc. Inhibition and reversion of chronic obstructive pulmonary disease (copd) by endothelial cell regeneration
US20240003871A1 (en) * 2022-06-29 2024-01-04 FUJIFILM Cellular Dynamics, Inc. Ipsc-derived astrocytes and methods of use thereof

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5486359A (en) 1990-11-16 1996-01-23 Osiris Therapeutics, Inc. Human mesenchymal stem cells
WO1999061587A1 (en) 1998-05-29 1999-12-02 Osiris Therapeutics, Inc. Human cd45+ and/or fibroblast + mesenchymal stem cells
US20030161818A1 (en) 2002-02-25 2003-08-28 Kansas State University Research Foundation Cultures, products and methods using stem cells
JP4790592B2 (ja) 2003-02-11 2011-10-12 ダビース，ジヨン・イー ヒト臍帯のウォートンジェリーからの前駆細胞
ES2569780T3 (es) 2003-06-27 2016-05-12 DePuy Synthes Products, Inc. Células posparto derivadas de tejido placentario y métodos de preparación y uso de las mismas
NZ553695A (en) * 2004-08-16 2009-10-30 Cellres Corp Pte Ltd Isolation of stem/progenitor cells from amniotic membrane of umbilical cord
WO2007106089A1 (en) 2006-03-14 2007-09-20 Spherical Dynamics, Inc. System for and method for psychological assessment
CN103356710A (zh) * 2007-02-12 2013-10-23 人类起源公司 利用胎盘干细胞治疗炎性疾病
PT103843B (pt) * 2007-10-04 2008-08-12 Medinfar Produtos Farmaceutico Método de isolamento de células precursoras a partir do cordão umbilical humano
EP2375907B1 (en) * 2008-11-21 2019-02-27 Celularity, Inc. Treatment of diseases, disorders or conditions of the lung using placental cells
CN101748096B (zh) 2008-12-17 2013-03-13 北京汉氏联合生物技术有限公司 亚全能干细胞、其制备方法及其用途
CA2756670A1 (en) 2009-03-26 2010-09-30 The Regents Of The University Of California Mesenchymal stem cells producing inhibitory rna for disease modification
MX337480B (es) 2009-09-23 2016-03-08 Davinci Biosciences Llc Celulas madre del revestimiento de cordon umbilical y metodos y material para aislar y cultivar las mismas.
CN101890050B (zh) 2010-07-14 2012-07-04 江苏大学 脐带间质干细胞来源膜性囊泡及其应用
EP2540819A1 (en) 2011-06-27 2013-01-02 Rheinisch-Westfälische Technische Hochschule Aachen (RWTH) Method for cultivating cells in platelet-lysate-containing medium
US20210355437A1 (en) 2015-09-02 2021-11-18 Restem Llc Factor rich product from umbilical cord mesenchymal stem cells

Also Published As

Publication number Publication date
EP2798058A1 (en) 2014-11-05
US9803176B2 (en) 2017-10-31
US20130216505A1 (en) 2013-08-22
HUE056817T2 (hu) 2022-03-28
US20220251513A1 (en) 2022-08-11
PL3321355T3 (pl) 2021-12-27
CA2862661A1 (en) 2013-07-04
CA3113484A1 (en) 2013-07-04
EP2798058B1 (en) 2017-10-18
PT3321355T (pt) 2021-09-28
SI3321355T1 (sl) 2021-11-30
US12441986B2 (en) 2025-10-14
US20220041992A1 (en) 2022-02-10
HRP20211373T1 (hr) 2021-11-26
US20220251514A1 (en) 2022-08-11
WO2013102219A1 (en) 2013-07-04
EP3321355A1 (en) 2018-05-16
US20250346865A1 (en) 2025-11-13
JP2015503918A (ja) 2015-02-05
JP6548897B2 (ja) 2019-07-24
DK3321355T3 (da) 2021-11-08
EP2798058A4 (en) 2015-05-20
US20260078347A1 (en) 2026-03-19
CA2862661C (en) 2021-05-25
EP3321355B1 (en) 2021-08-25
ES2656614T3 (es) 2018-02-27
US20220251515A1 (en) 2022-08-11
US20190218519A1 (en) 2019-07-18

Similar Documents

Publication Publication Date Title
US12441986B2 (en) Methods and compositions for the clinical derivation of a stem cell and therapeutic uses
ES2776408T3 (es) Método de proliferación celular y agente farmacéutico para reparación y regeneración de tejido
ES2755551T3 (es) Composiciones que tienen contenidos plaquetarios
ES2613930T3 (es) Procedimiento de cultivo de células procedentes de tejido adiposo y sus aplicaciones
ES2373551T3 (es) Métodos para usar células derivadas de tejido adiposo en el tratamiento de afecciones cardiovasculares.
ES2710099T3 (es) Progenie de células precursoras mesenquimales expandidas multipotenciales (MEMP) y sus usos
CN101272798B (zh) 基因修饰以表达自杀基因的骨髓间充质干细胞在制造用于治疗癌症的药物中的用途
WO2007015546A1 (ja) 間葉系幹細胞誘導剤及び組織再生促進剤並びに間葉系幹細胞の調製方法
JP7044429B1 (ja) 腫瘍を縮小、又は消失させるための組成物
US20190255117A1 (en) Synoviolin expression inhibitor containing mesenchymal stem cell or culture supernatant thereof
KR102306231B1 (ko) 편도 유래 중간엽 줄기세포로부터 건 세포의 분화방법
Yang et al. Cardiac myocyte progenitors from adult hearts for myocardial regenerative therapy
Sawa Current status of myocardial regeneration therapy
ES2366701T3 (es) Técnicas in vitro para su uso con células madre.
US20100226894A1 (en) Mobilization of a complete cells mixture with embryonic like stem cells from the peripheral blood
JP2009065854A (ja) 細胞増殖方法ならびに組織の修復および再生のための医薬
HL 3rd EACTS Meeting on Cardiac and Pulmonary Regeneration Berlin-Brandenburgische Akademie, Berlin, Germany, 14–15 December 2012
KR20210046196A (ko) 말과동물 양막-유래 중간엽 줄기세포 및 이의 용도
Poole Cardiovascular therapeutics derived from the paracrine biology of adult human progenitor cells
KR20160125759A (ko) 인간 피부조직 유래 성체줄기세포 및 이를 함유하는 세포치료제
JPWO2016072105A1 (ja) 重層上皮組織形成能を有する細胞、及びその製造方法
HK1102085B (en) Methods of using adipose tissue-derived cells in the treatment of cardiovascular conditions